IRLAB Therapeutics AB (OSTO:IRLAB A) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)

What is IRLAB Therapeutics AB LT-Debt-to-Total-Asset?

IRLAB Therapeutics AB OSTO:IRLAB A +0.16% 36 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates OSTO:IRLAB A with a GF Score™ of 36/100 and a GF Value™ of kr11.76 (Possible Value Trap). The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. IRLAB Therapeutics AB's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

IRLAB Therapeutics AB's long-term debt to total assets ratio declined from Mar. 2025 (0.02) to Mar. 2026 (0.00). It may suggest that IRLAB Therapeutics AB is progressively becoming less dependent on debt to grow their business.

IRLAB Therapeutics AB (OSTO:IRLAB A) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

IRLAB Therapeutics AB LT-Debt-to-Total-Asset Related Terms

IRLAB Therapeutics AB LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for IRLAB Therapeutics AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IRLAB Therapeutics AB LT-Debt-to-Total-Asset Chart

IRLAB Therapeutics AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.00

0.14

0.03

0.00

IRLAB Therapeutics AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.02	0.02	0.15	0.00	0.00

36GF Score

IRLAB Therapeutics AB OSTO:IRLAB A

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

IRLAB Therapeutics AB LT-Debt-to-Total-Asset Calculation

IRLAB Therapeutics AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	0	/	140.804
	=	0.00

IRLAB Therapeutics AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	0	/	135.031
	=	0.00

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

IRLAB Therapeutics AB (OSTO:IRLAB A) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on IRLAB Therapeutics AB and its competitors.

Is IRLAB Therapeutics AB's LT-Debt-to-Total-Asset too high?

IRLAB Therapeutics AB's current LT-Debt-to-Total-Asset is 0.00. Overall, IRLAB Therapeutics AB has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does IRLAB Therapeutics AB's LT-Debt-to-Total-Asset compare to VRTX and REGN?

IRLAB Therapeutics AB's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on IRLAB Therapeutics AB and its competitors. IRLAB Therapeutics AB's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is IRLAB Therapeutics AB stock overvalued right now?

Based on GuruFocus' analysis, IRLAB Therapeutics AB (OSTO:IRLAB A) is currently considered Possible Value Trap. The stock's GF Value™ is kr11.76, compared to a current price of kr1.24 — trading 89.4% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. IRLAB Therapeutics AB's overall GF Score™ is 36/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For IRLAB Therapeutics AB (OSTO:IRLAB A), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IRLAB Therapeutics AB (OSTO:IRLAB A) Overvalued in 2026?

Based on GuruFocus' analysis, IRLAB Therapeutics AB stock appears to be undervalued. The current stock price of kr1.24 is trading 89.4% below its estimated GF Value™ of kr11.76. GuruFocus considers IRLAB Therapeutics AB to be Possible Value Trap.

Key valuation signals for OSTO:IRLAB A:

LT-Debt-to-Total-Asset: 0.00
GF Value™: kr11.76 vs. price of kr1.24 (89.4% below fair value)
GF Score™: 36/100 with 6 warning signs

No single metric tells the full story. See the OSTO:IRLAB A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IRLAB Therapeutics AB Business Description

Industry Healthcare Biotechnology

Comparable Companies OSTO:ATORX OSTO:BIOVIC B OSTO:ALZ OSTO:NXTCL OSTO:CMOTEC B OSTO:SIMRIS B OSTO:ANNX OSTO:ONCOZ OSTO:SPAGO OSTO:ACOU VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 6IRA:Germany

Address Arvid Wallgren Backe 20, Goteborg, SWE, 413 46

Website https://www.irlab.se

IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds that aims to offer improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

36GF Score

Get the complete analysis for OSTO:IRLAB A

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.24

Price

kr11.76

GF Value

View OSTO:IRLAB A Analysis

See LT-Debt-to-Total-Asset data for all stocks →